Evidence map›Paper›PMID 34539631›Full record

ArticleFrontiers in immunology2021

Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.

Maria J Pons, Barbara Ymaña, Ana Mayanga-Herrera, Yolanda Sáenz, Lydia Alvarez-Erviti, Salyoc Tapia-Rojas, Roxana Gamarra, Amanda B Blanco, Gemma Moncunill, Manuel F Ugarte-Gil

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Infectious Diseases.Advances in neurobiology · 2024
    Review
  8. Article
  9. Article
  10. The Prognostic Utility of Cytokines in Hospitalized COVID-19 Patients.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Maria J PonsGrupo Enfermedades Emergentes, Universidad Científica del Sur, Lima, Peru.
Barbara YmañaGrupo Enfermedades Emergentes, Universidad Científica del Sur, Lima, Peru.
Ana Mayanga-HerreraLaboratorio de Cultivo Celular e Inmunología, Universidad Científica del Sur, Lima, Peru.
Yolanda SáenzÁrea de Microbiología Molecular, Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, Spain.
Lydia Alvarez-ErvitiÁrea de Neurobiología Molecular, Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, Spain.
Salyoc Tapia-RojasLaboratorio de Cultivo Celular e Inmunología, Universidad Científica del Sur, Lima, Peru.
Roxana GamarraHospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Amanda B BlancoHospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Gemma MoncunillISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Manuel F Ugarte-GilGrupo Enfermedades Emergentes, Universidad Científica del Sur, Lima, Peru.
Universidad Científica del Sur · PEHospital Base Guillermo Almenara Irigoyen · PECenter for Biomedical Research of La Rioja · ESBarcelona Institute for Global Health · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokines, chemokines and growth factors present different expression profiles related to the prognosis of COVID-19. We analyzed clinical parameters and assessed the expression of these biomarkers in patients with different disease severity in a hospitalized Peruvian cohort to determine those associated with worse prognosis. We measured anti-spike IgG antibodies by ELISA and 30 cytokines by quantitative suspension array technology in 123 sera samples. We analyzed differences between patients with moderate, severe and fatal COVID-19 by logistic regression at baseline and in longitudinal samples. Significant differences were found among the clinical parameters: hemoglobin, neutrophils, lymphocytes and C-reactive protein (CRP), creatinine and D-dimer levels. Higher anti-spike IgG antibody concentrations were associated to fatal patient outcomes. At hospitalization, IL-10, IL-6, MIP-1α, GM-CSF, MCP-1, IL-15, IL-5, IL1RA, TNFα and IL-8 levels were already increased in fatal patients´ group. Meanwhile, multivariable analysis revealed that increased GM-CSF, MCP-1, IL-15, and IL-8 values were associated with fatal outcomes. Moreover, longitudinal analysis identified IL-6 and MCP-1 as the main risk factors related to mortality in hospitalized COVID-19 patients. In this Peruvian cohort we identified and validated biomarkers related to COVID-19 outcomes. Further studies are needed to identify novel criteria for stratification of SARS-CoV-2 infected patients at hospital entry. Background: In the most severe forms of SARS-CoV-2 infection, large numbers of innate and adaptive immune cells become activated and begin to produce pro-inflammatory cytokines, establishing an exacerbated feedback loop of inflammation. Methods: A total of 55 patients with laboratory-confirmed COVID-19 admitted to the Results: The frequency of obesity differed among the 3 groups, being most frequent in patients who died. There were also significant differences in clinical parameters: hemoglobin, segmented neutrophils, lymphocytes,C-reactive protein, creatinine and D-dimer levels. Greater anti-spike IgG antibody concentrations were associated to fatal outcomes. In univariate analyses, higher baseline concentrations of IL-6, MIP-1α, GM-CSF, MCP-1, IL-15, IL-5, IL1RA, TNFα, IL-8 and IL-12p70 correlated with severity, while multivariable analysis showed that increased concentrations in 4 biomarkers (GM-CSF, MCP-1, IL-15, IL-8) were associated with fatal outcomes. Longitudinal analysis showed IL-6 (hazard ratio [HR] 6.81, 95% confidence interval [CI] 1.6-28.7) and MCP-1 (HR 4.61, 95%CI 1.1-19.1) to be related to mortality in hospitalized COVID-19 patients. Conclusions: Cytokine, chemokine and growth factor profiles were identified and validated related to severity and outcomes of COVID-19. Our findings may be useful to identify novel criteria for COVID-19 patient stratification at hospital entry.

Indexed as

Antibodies, ViralBiomarkersComorbidityCOVID-19CytokinesEnzyme-Linked Immunosorbent AssayFemaleHospitalizationHumansImmunoglobulin GMaleMiddle AgedObesityPeruPrognosisSARS-CoV-2Antibodies, ViralBiomarkersCytokinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2biomarkersCOVID-19cytokineprognosisproinflammatorySARS-CoV-2 IgG

Identifiers

PMID34539631
PMCPMC8440968
OpenAlexW3196370454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.